Cell>Point News & Publications

Diagnostic Imaging

CellPoint, L.L.C. announced today that it has entered into automated production agreement with KP Pharmaceutical Technologies for lead molecular imaging agent Oncardia®

Posted on: September 19th, 2018

CENTENNIAL, Colorado, September 18, 2018 – CellPoint announced today that it has entered into an automated production agreement with KP Pharmaceutical Technology, Inc. to produce 1mg vials of its lead agent Oncardia®(ethylenedicysteine-glucosamine).   CellPoint is currently completing Phase 2b and 3 nuclear imaging trials with 99mTc-Oncardia® in both cardiology and oncology imaging. The new formulation will simplify the…

Read More

Noninferiority of 99mTc Ethylenedicystein Glucosamine (Oncarida) as a Alternative Analogue to 18F Flurodeoxyglucose in the Detection and Staging of Non Small Cell Lung Cancer

Posted on: March 19th, 2018

Published March 19, 2018, Hindawi Contrast Media & Molecular Imaging https://cellpointweb.com/wp-content/uploads/2019/11/Noninferiority-of-99mTc-Ethylenedicystein.pdf

Read More

Targeting the Hexosamine Biosynthetic Pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma

Posted on: October 3rd, 2016

Oncotarget, Advance Publications 2016 https://cellpointweb.com/wp-content/uploads/2019/11/12413-186535-1-PB-2016-EC-G-Paper.pdf

Read More

Cell>Point enters into license agreement with Vyripharm Biopharmaceuticals for the use of Cell>Point’s In-Situ Hydrogel, N4 Technology and Oligosaccharide (Dual Agent) Technology

Posted on: August 25th, 2016

CENTENNIAL, Colo., August 24, 2016  – Cell>Point today announced it has entered into license agreements with Vyripharm Biopharmaceuticals for the use of its In-Situ Hydrogel, N4 Technology and Oligosaccharide (Dual Agent) Technology to develop applications in combination with cannabinoids for nuclear imaging and therapeutic applications for neurologic disorders including, but not limited to, posttraumatic stress disorder (“PTSD”),…

Read More

Cell>Point Executes China License with United Eastern Pharmaceutical for Oncardia® for Cancer and Heart Disease Diagnostic Imaging

Posted on: June 17th, 2016

CENTENNIAL, Colo., June 16, 2016 – Cell>Point today announced that it has entered into an exclusive license agreement for China, Hong Kong and Macau with United Eastern Pharmaceutical (UEP), a company representing a consortium from the U.S. and China. The license agreement covers Cell>Point’s diagnostic radiopharmaceutical Oncardia® (ethylenedicysteine-glucosamine) which was developed for labeling with technetium-99m for…

Read More

Cell>Point Announces Postive Results from 99mTc-Oncardia® (EC- G) trial at the Unviersity of Chicago Medical Center to image and montior therapy for Head and Neck Cancer.

Posted on: February 26th, 2015

CENTENNIAL, Colo., January 15, 2015 – Cell>Point announced today positive results following conclusion of a Head and Neck Cancer imaging trial for 99mTc-Oncardia® conducted pursuant to a  physician initiated IND study at the University of Chicago Medical Center. The study imaged patients with squamous cell carcinoma of the head and neck (SCCHN) with technetium-99m- labeled Oncardia®…

Read More

Patched Targeted Peptides for Imaging and Treatment of Hedgehog Positive Breast Tumors

Posted on: September 21st, 2014

Published: September 2014, Bio Medical Research International https://cellpointweb.com/wp-content/uploads/2019/11/Patched-Targeting-Peptides-for-Imaging-and-Treatment-of-Hedgehog-Postive-Breast-Tumors.pdf

Read More

Cell>Point Announces Encouraging Results from 99mTc -EC-G Phase 2a Trial in Evaluating Presence and Severity of Coronary Artery Disease

Posted on: April 12th, 2013

CENTENNIAL, Colo., April 9, 2013—Cell>Point announced today encouraging results following the conclusion of its Phase 2a cardiovascular clinical study performed by Cardiovascular Imaging Technologies of Kansas City, Missouri. The study imaged patients with technetium-99m-labeled Ethylenedicysteine-Glucosamine (99mTc-EC-G), Cell>Point’s proprietary nuclear imaging product candidate, which is target specific for detecting the presence and extent of  schemia in patients with Coronary…

Read More

Cell>Point and HYUN IMC Expand License in South Korea to Include Hanmi Pharmaceutical, Co., Ltd for Cancer and Heart Disease Imaging

Posted on: March 13th, 2013

Third License Completes the Company’s Initiative to Secure a Strong Pharmaceutical  Partner for the South Korean Market CENTENNIAL, Colo., March 11, 2013—Cell>Point announced today that it entered into a license agreement on December 17,2012 with Hanmi Pharmaceutical Co., Ltd (Hanmi) who is headquartered in Seoul, Korea. The license agreement also includes HYUN IMC as a party (who Cell>Point previously…

Read More

Development of 99mTc-EC-tyrosine for Early Detection of Breast Cancer Tumor Response to the Anticancer Drug Melphalan

Posted on: January 30th, 2013

Published: January 2013, Vol. 20, No. 1, Academic Radiology https://cellpointweb.com/wp-content/uploads/2019/11/Deveopment-of-99mTc-EC-tyrosine-for-Early-Detection-of-Breast-Cancer-Tumror-Response-to-the-Anticancer-Drug-Melphalan.pdf

Read More